JP6165852B2 - 睡眠障害を治療するためのグレリン受容体逆アゴニストまたはアンタゴニストの使用 - Google Patents

睡眠障害を治療するためのグレリン受容体逆アゴニストまたはアンタゴニストの使用 Download PDF

Info

Publication number
JP6165852B2
JP6165852B2 JP2015515606A JP2015515606A JP6165852B2 JP 6165852 B2 JP6165852 B2 JP 6165852B2 JP 2015515606 A JP2015515606 A JP 2015515606A JP 2015515606 A JP2015515606 A JP 2015515606A JP 6165852 B2 JP6165852 B2 JP 6165852B2
Authority
JP
Japan
Prior art keywords
patient
sleep
ghrelin
pharmaceutically acceptable
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015515606A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015518876A5 (enExample
JP2015518876A (ja
Inventor
エス． デニー ウィリアム
エス． デニー ウィリアム
ジャクソン マーガレット
ジャクソン マーガレット
ソンネンバーグ ガブリエール
ソンネンバーグ ガブリエール
Original Assignee
ファイザー・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・インク filed Critical ファイザー・インク
Publication of JP2015518876A publication Critical patent/JP2015518876A/ja
Publication of JP2015518876A5 publication Critical patent/JP2015518876A5/ja
Application granted granted Critical
Publication of JP6165852B2 publication Critical patent/JP6165852B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015515606A 2012-06-04 2013-05-21 睡眠障害を治療するためのグレリン受容体逆アゴニストまたはアンタゴニストの使用 Expired - Fee Related JP6165852B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261655177P 2012-06-04 2012-06-04
US61/655,177 2012-06-04
US201361812416P 2013-04-16 2013-04-16
US61/812,416 2013-04-16
PCT/IB2013/054177 WO2013182933A1 (en) 2012-06-04 2013-05-21 Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders

Publications (3)

Publication Number Publication Date
JP2015518876A JP2015518876A (ja) 2015-07-06
JP2015518876A5 JP2015518876A5 (enExample) 2016-07-07
JP6165852B2 true JP6165852B2 (ja) 2017-07-19

Family

ID=48700662

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015515606A Expired - Fee Related JP6165852B2 (ja) 2012-06-04 2013-05-21 睡眠障害を治療するためのグレリン受容体逆アゴニストまたはアンタゴニストの使用

Country Status (16)

Country Link
US (1) US9370516B2 (enExample)
EP (1) EP2854856B1 (enExample)
JP (1) JP6165852B2 (enExample)
KR (1) KR101708989B1 (enExample)
CN (1) CN104334193A (enExample)
AU (1) AU2013273263B2 (enExample)
BR (1) BR112014029577A2 (enExample)
CA (1) CA2874196C (enExample)
ES (1) ES2716303T3 (enExample)
HK (1) HK1202459A1 (enExample)
IL (1) IL235883A0 (enExample)
MX (1) MX2014014813A (enExample)
RU (1) RU2600895C2 (enExample)
SG (1) SG11201407387UA (enExample)
WO (1) WO2013182933A1 (enExample)
ZA (1) ZA201408672B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105175272A (zh) * 2015-08-31 2015-12-23 吴玲 制备r-5-溴-1-氨基茚满的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
WO2004058160A2 (en) * 2002-12-20 2004-07-15 The Mclean Hospital Corporation Compounds for the normalization of the sleep/wake cycle
US20050171132A1 (en) * 2003-09-26 2005-08-04 Zhili Xin Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonists
JP2007537207A (ja) * 2004-05-14 2007-12-20 ノボ　ノルディスク　アクティーゼルスカブ 一定の中枢神経疾患の治療のためのグレリンアンタゴニストの使用
US20090253673A1 (en) * 2006-07-12 2009-10-08 Min Ge Substituted Pyrazoles as Ghrelin Receptor Antagonists
US8309530B2 (en) * 2009-02-04 2012-11-13 Washington State University Compositions and methods for modulating ghrelin-mediated conditions
ES2557895T3 (es) * 2010-03-19 2016-01-29 Pfizer Inc Derivados de 2,3-dihidro-1H-inden-1-il-2,7-diazaespiro[3.6]nonano y su uso como antagonistas o agonistas inversos del receptor de grelina

Also Published As

Publication number Publication date
KR20150013236A (ko) 2015-02-04
US9370516B2 (en) 2016-06-21
MX2014014813A (es) 2015-02-12
AU2013273263A1 (en) 2014-11-27
EP2854856B1 (en) 2019-01-23
JP2015518876A (ja) 2015-07-06
US20150119381A1 (en) 2015-04-30
HK1202459A1 (en) 2015-10-02
CA2874196A1 (en) 2013-12-12
WO2013182933A1 (en) 2013-12-12
AU2013273263B2 (en) 2017-08-24
RU2600895C2 (ru) 2016-10-27
CN104334193A (zh) 2015-02-04
ZA201408672B (en) 2016-09-28
CA2874196C (en) 2016-12-06
KR101708989B1 (ko) 2017-02-21
SG11201407387UA (en) 2014-12-30
ES2716303T3 (es) 2019-06-11
IL235883A0 (en) 2015-01-29
EP2854856A1 (en) 2015-04-08
RU2014146109A (ru) 2016-07-27
BR112014029577A2 (pt) 2017-06-27

Similar Documents

Publication Publication Date Title
JP5076159B2 (ja) アセチルコエンザイムａカルボキシラーゼ（ａｃｃ）阻害薬としてのスピロクロマノン誘導体
CN103874695B (zh) 2‑吡啶基氧基‑4‑腈食欲素受体拮抗剂
ES2397188T3 (es) Compuestos de diazepano sustituidos como antagonistas del receptor de orexina
US9586934B2 (en) 2-pyridyloxy-4-methyl orexin receptor antagonists
JP5639564B2 (ja) ピリジルピペリジン・オレキシン受容体アンタゴニスト
JP5635991B2 (ja) イソニコチンアミドオレキシン受容体アンタゴニスト
US9828368B2 (en) Oxazole orexin receptor antagonists
JP2009516742A (ja) インドールオレキシン受容体アンタゴニスト
JP2012506376A (ja) ２，５−二置換モルホリンオレキシン受容体アンタゴニスト
JP2009542809A (ja) グレリン受容体アンタゴニストとしての置換ピラゾール
JP2012507539A (ja) ２，５−二置換フェニルカルボキサミド・オレキシン受容体アンタゴニスト
JP2012507540A (ja) ピリダジンカルボキサミド・オレキシン受容体アンタゴニスト
JP2012506374A (ja) ２，５−二置換ピペリジンオレキシン受容体アンタゴニスト
JP2011530522A (ja) トリピリジルカルボキサミドオレキシン受容体拮抗薬
JP2012506378A (ja) ２，３−二置換フェニルカルボキサミド・オレキシン受容体アンタゴニスト
US20150322039A1 (en) 2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists
JP2012506377A (ja) ２，４−二置換フェニルカルボキサミド・オレキシン受容体アンタゴニスト
US20170320865A1 (en) Oxazole orexin receptor antagonists
US20170313684A1 (en) Pyrazole orexin receptor antagonists
JP2009506061A (ja) ジアザスピロデカンオレキシン受容体拮抗薬
JP5319518B2 (ja) インドールジオン誘導体
WO2006076796A1 (en) Cathepsin k inhibitors and obesity
US9370516B2 (en) Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160519

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170605

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170621

R150 Certificate of patent or registration of utility model

Ref document number: 6165852

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees